Methylene blue human studies: what the evidence really shows

Last updated 2026-07-27

What is methylene blue actually approved for in humans?

Methylene blue (methylthioninium chloride) has exactly one FDA-approved indication: treatment of acquired methemoglobinemia, a condition where hemoglobin gets stuck in a form that can't carry oxygen. The approved injectable product, Provayblue, carries this label indication and a standard dose range of 1 to 2 mg/kg given intravenously over several minutes ^[1]. That approval is based on decades of clinical use dating back over a century, not a modern trial program built around cognition or energy. Everything else you hear about methylene blue, mitochondrial support, focus, memory, anti-aging, is off-label. That doesn't automatically mean it's wrong or dangerous at the right dose. It means the FDA has not reviewed and approved it for those uses, and the evidence base is a lot smaller and shakier than the marketing around it suggests. This distinction matters for practical reasons too. An approved drug used off-label still has to come from a real pharmaceutical source with actual quality control. A lot of what's sold online as "methylene blue" for nootropic use is not pharmaceutical grade at all, and that gap is where real harm happens.

Is there real human evidence for methylene blue and memory or cognition?

There is some, but it's small, old-ish, and narrow. The most cited human work comes from a research group led by Gary Wenk and Francisco Gonzalez-Lima, published around 2011 to 2016, testing low-dose methylene blue (roughly 0.5 mg/kg orally) on memory tasks and brain imaging in healthy adults. One frequently referenced study, published in Radiology in 2012, used fMRI to show increased brain activity in regions tied to short-term memory and visual attention after a single low dose in a small sample of healthy volunteers ^[2]. A related trial found improved recall on an emotional memory task at that same low dose, again in a small healthy-volunteer sample, with the effect notably not present at higher doses. That's a pattern that shows up repeatedly in this literature: low doses (around 0.5 to 1 mg/kg) sometimes look mildly stimulating to mitochondrial and cognitive markers, while higher doses (4 mg/kg and up) tend to look sedating or even mildly impairing in some measures. This is often called a hormetic or biphasic dose-response, and it means you cannot extrapolate from "more is better" the way you might with a stimulant. What's missing is any large, replicated, placebo-controlled trial in a real target population, say, people with age-related memory complaints or diagnosed mild cognitive impairment, powered to detect a clinically meaningful difference. What exists is proof-of-concept work in small groups of healthy young adults. That's a reasonable first step in drug development. It is not the same as evidence that methylene blue improves focus or memory in the population buying it online. If you're trying to figure out a rational dose from this literature, the Methylene Blue Bio dosage guide and Methylene Blue Bio dosage calculator walk through how the low-dose range in these studies compares with what's typically discussed for off-label use, and why higher isn't better here.

What about methylene blue for Alzheimer's disease? Did the human trials work?

This is the most studied disease application, and the honest answer is: mixed, with one high-profile miss. Methylene blue's reduced form is chemically related to a compound called LMTX (leuco-methylthioninium), which TauRx Pharmaceuticals developed as a tau-aggregation inhibitor for Alzheimer's disease. TauRx ran two Phase 3 trials (LMTX in mild-to-moderate Alzheimer's) enrolling over 1,100 patients combined. The results, published in The Lancet Neurology in 2018, found that LMTX did not improve cognitive or functional outcomes as an add-on to standard Alzheimer's therapy, though a subgroup taking it as monotherapy showed some effect, a result the authors and outside reviewers treated cautiously because of how the data was analyzed ^[3]. A later 2020 trial in behavioral variant frontotemporal dementia also failed to meet its primary endpoint ^[4]. So the tau-related, disease-modifying story for methylene blue derivatives has real, controlled Phase 3 human data behind it, and that data has not been a clean win. This is worth knowing before anyone assumes methylene blue is a proven anti-dementia agent. It's an active area of study, not a settled one.

Does methylene blue actually improve mitochondrial function in people, or just in cells and animals?

The mitochondrial story for methylene blue is mostly a cell-and-rodent story. In isolated mitochondria and cell culture, methylene blue can act as an alternative electron carrier, shuttling electrons in the mitochondrial respiratory chain when normal complex I/III function is impaired, an effect described in pharmacology reviews going back over a decade ^[5]. In rodent models of aging, traumatic brain injury, and neurodegeneration, low-dose methylene blue has shown effects on oxidative stress markers and, in some studies, improved learning and memory performance. Human confirmation of a mitochondrial mechanism is much thinner. The human fMRI and memory studies mentioned above are consistent with something happening at low dose, and some researchers argue the effect is mediated through improved cellular respiration in metabolically demanding brain regions. But no human trial has directly measured mitochondrial ATP output or oxidative phosphorylation efficiency in people taking methylene blue and tied that directly to a functional outcome like sustained energy or fatigue reduction. So when you see "boosts mitochondria" claims attached to methylene blue for energy or longevity, that's a real and interesting mechanism supported by lab and animal data, stretched further than current human evidence supports. Be honest with yourself about that gap before paying a premium for it.

Is methylene blue an MAOI, and why does that matter for people combining it with other drugs?

Yes, and this is probably the single most important safety fact in this whole topic. Methylene blue inhibits monoamine oxidase A (MAO-A), meaning it slows the breakdown of serotonin in the brain. The FDA added a boxed warning to methylene blue's label specifically about the risk of serotonin syndrome when it's given to patients on serotonergic drugs, including SSRIs, SNRIs, MAOIs, and several other classes ^[6]. The FDA's own drug safety communication, issued in 2011, states plainly: "Methylene blue can cause a serious drug interaction when given to patients taking serotonergic psychiatric medications," and lists cases of serotonin syndrome, some severe, associated with this combination . Symptoms include agitation, high fever, tremor, muscle rigidity, and in severe cases, seizures and death. This isn't a theoretical interaction, it's documented in the label and in published case reports, mostly from surgical settings where methylene blue was given intravenously to patients already on antidepressants. If you take any SSRI (fluoxetine, sertraline, escitalopram, etc.), any SNRI (venlafaxine, duloxetine), tramadol, triptans, or another MAOI, methylene blue is not something to combine casually, oral low-dose or otherwise, without talking to a prescriber who knows your full medication list. This is not a place to guess.

Who should not take methylene blue at all?

The clearest, best-documented contraindication is G6PD deficiency (glucose-6-phosphate dehydrogenase deficiency), a common genetic enzyme deficiency affecting an estimated 400 million people worldwide, with higher prevalence in people of African, Mediterranean, and Southeast Asian descent . Methylene blue relies on G6PD-dependent pathways to get reduced back to its active form, and in people who lack sufficient G6PD, it can trigger severe hemolytic anemia instead of helping. Provayblue's label carries a specific contraindication for G6PD deficiency ^[1]. Beyond G6PD status, people on serotonergic medications (see above), pregnant or breastfeeding people (data is limited and it does cross the placenta), people with significant kidney impairment (it's renally cleared), and anyone with a known hypersensitivity to methylene blue or thiazine dyes should avoid it outside of direct medical supervision. If you don't know your G6PD status and you're considering methylene blue for any reason, that's a blood test to get first, not a risk to shrug off.

What's the difference between pharmaceutical-grade methylene blue and the stuff sold for aquariums?

This is not a marketing distinction, it's a real difference in what's in the bottle. Pharmaceutical-grade methylene blue meets USP (United States Pharmacopeia) monograph standards for identity, purity, and limits on heavy metals and other contaminants, and it's manufactured under FDA-regulated conditions ^[1]. Aquarium-grade or industrial-grade methylene blue, sold for fish tank treatment or as a laboratory stain, has no such requirement. It can legally contain heavy metal contaminants, inconsistent concentrations, and other impurities that were never designed to go anywhere near a human body. There is no regulatory body checking that the methylene blue in a pet store bottle is safe for oral or injectable human use, because it was never intended for that. Reports of contamination in non-pharmaceutical methylene blue products are part of why poison control centers and pharmacology references consistently flag this as a real risk, not a theoretical one. If you're going to use methylene blue for anything, off-label or not, USP pharmaceutical grade from a legitimate pharmacy source is the only reasonable starting point. Methylene Blue Bio's model is built around this exact gap: connecting people with provider review and a pharmacy partner that fulfills pharmaceutical-grade product, rather than leaving people to guess at purity from an unregulated bottle.

How much human safety data exists at the doses people use for energy or focus?

More than you'd think for the drug as a whole, less than you'd want for this specific use case. Methylene blue has been used clinically for methemoglobinemia, malaria (historically), and as a surgical dye for over 100 years, so acute safety at clinical IV doses (1 to 2 mg/kg) is reasonably well characterized ^[1]. Common side effects at those doses include blue-green urine discoloration, nausea, dizziness, and headache; at higher doses (over 7 mg/kg), it can actually worsen methemoglobinemia rather than treat it, a paradoxical effect noted in the prescribing information ^[1]. What's thinner is repeated, chronic, low-dose oral use in healthy people over months or years, the pattern most nootropic users are actually doing. The human cognition trials used single doses or short courses, not sustained daily dosing over a year. Long-term safety data at the low doses people take for "energy" or "focus" essentially doesn't exist in controlled human trials. That's an honest gap, not a reason to panic, but a reason to be conservative about duration and to track how you're doing. Anyone starting a course should think in terms of a defined cycle length rather than open-ended daily use, precisely because the long-duration human data isn't there yet.

How is methylene blue actually dosed and administered in the studies that exist?

Across the human cognition and safety literature, doses cluster in a few recognizable bands. The table below pulls together the dose ranges from different contexts, so you can see how far apart clinical treatment and the low-dose "nootropic" range really are. | Context | Typical dose | Route | Source |

Are there human studies on methylene blue and aging or longevity specifically?

Not really, not in the sense of a trial measuring lifespan or a validated aging biomarker in humans. The longevity claim rests almost entirely on mitochondrial mechanism arguments and rodent lifespan/healthspan studies, some of which show benefits in specific stressed or aged animal models, plus the general (and reasonable) idea that mitochondrial dysfunction tracks with aging phenotypes. No published human RCT has used methylene blue with aging biomarkers (epigenetic clocks, senescent cell burden, grip strength trajectories, whatever metric you'd pick) as a primary endpoint. That's a real gap, and anyone telling you methylene blue is a proven longevity intervention in humans is overstating the current literature, full stop. It might be a promising mechanism worth studying. It is not a demonstrated human longevity drug.

What should someone actually do with this evidence if they're considering methylene blue off-label?

Start from what's solid: it's an FDA-approved drug for methemoglobinemia with a century of clinical use, a well-documented MAOI interaction risk, a real G6PD contraindication, and a small but genuinely interesting human cognition literature at very specific low doses. Build your decision on those facts, not on the marketing layer sitting on top of them. Practically, that means three things. Get your G6PD status checked before you start anything. Have an honest conversation, ideally with a prescriber, about every serotonergic medication or supplement you're on, because the interaction risk is not rare or exotic, the FDA put a formal warning on it. And source only USP pharmaceutical-grade product through a legitimate pharmacy, never aquarium or industrial-grade material, regardless of how it's marketed. A provider-reviewed pathway, where a clinician actually looks at your history before product ships from a real pharmacy, is a meaningfully different risk profile than ordering an unlabeled vial online. That's the model Methylene Blue Bio is built around: provider review paired with a pharmacy partner that fulfills pharmaceutical-grade methylene blue, not a company that compounds or manufactures it themselves.

Frequently asked questions

Is methylene blue FDA-approved for energy, focus, or anti-aging?

No. Methylene blue's only FDA-approved use is treating acquired methemoglobinemia, per its prescribing information ^[1]. Any use for energy, cognition, focus, or longevity is off-label, meaning it's not an indication the FDA reviewed or approved, regardless of how it's marketed online.

What human studies exist on methylene blue and memory?

A small line of research, largely from the early 2010s, found that a single low oral dose (about 0.5 mg/kg) improved certain memory tasks and increased fMRI activity in memory-related brain regions in healthy volunteers ^[2]. These were small, short-duration studies, not large trials in people with diagnosed memory impairment.

Did methylene blue work in Alzheimer's clinical trials?

Results were mixed and largely negative on primary endpoints. Two Phase 3 trials of LMTX, a related compound, in over 1,100 Alzheimer's patients found no clear benefit as an add-on therapy, per The Lancet Neurology, 2018 ^[3]. A subgroup on monotherapy showed some signal, but it wasn't a clean, confirmed result.

Can methylene blue cause serotonin syndrome?

Yes. Methylene blue inhibits MAO-A and the FDA issued a specific drug safety communication warning that combining it with SSRIs, SNRIs, or other serotonergic drugs can cause serotonin syndrome, a potentially serious reaction ^[7]. This is a labeled warning, not a rare theoretical risk, and it applies at low oral doses too, more than IV clinical doses.

Who should never take methylene blue?

People with G6PD deficiency, a genetic condition affecting roughly 400 million people worldwide, should avoid methylene blue because it can trigger severe hemolytic anemia in this group ^[8]. People on serotonergic medications, those with significant kidney impairment, and pregnant or breastfeeding people should also avoid it without direct medical guidance.

What's the difference between pharmaceutical-grade and aquarium-grade methylene blue?

Pharmaceutical-grade (USP) methylene blue meets FDA-regulated purity and contaminant standards. Aquarium or industrial-grade methylene blue has no such requirement and can contain heavy metals or inconsistent concentrations, since it was never intended for use in or on the human body. Using non-pharmaceutical grade product is a genuine, avoidable safety risk.

Does methylene blue really boost mitochondria in humans?

The mitochondrial mechanism (acting as an alternative electron carrier) is well documented in cell and animal studies, but no human trial has directly measured mitochondrial ATP output in people taking methylene blue and linked it to a functional outcome like energy or fatigue. The human cognition data is suggestive, not a confirmed mitochondrial mechanism in people.

What dose of methylene blue is used in human research?

Cognition studies in healthy adults have used roughly 0.5 mg/kg orally as a low dose and around 4 mg/kg as a higher comparison dose, with the lower dose showing more consistent benefit ^[2]. Clinical treatment of methemoglobinemia uses 1-2 mg/kg IV ^[1]. These are different contexts and shouldn't be conflated.

Is methylene blue safe to take every day long-term?

There's limited controlled human data on daily, low-dose oral use over months or years. Most trials tested single or short-course doses. That's a genuine gap in the evidence, which is why a defined cycle length rather than indefinite daily use is the more conservative approach until better long-term data exists.

Can methylene blue interact with other medications besides antidepressants?

Yes. Beyond SSRIs and SNRIs, it can interact with other MAOIs, tramadol, triptans, and other serotonergic or MAO-affecting drugs. The FDA safety communication specifically lists multiple drug classes at risk for interaction ^[7]. Anyone on a regular medication should review their full list with a prescriber before starting methylene blue.

Has methylene blue been proven to slow aging in humans?

No. There is no published human trial using methylene blue with aging-specific endpoints like epigenetic age or senescent cell markers. The longevity claim rests on mitochondrial mechanism arguments and animal studies, not demonstrated human outcomes, so it should be treated as an unproven hypothesis rather than an established benefit.

What side effects show up in human methylene blue studies?

At clinical IV doses, documented effects include blue-green urine discoloration, nausea, dizziness, and headache, per the Provayblue prescribing information ^[1]. At doses above roughly 7 mg/kg, methylene blue can paradoxically worsen methemoglobinemia rather than treat it, a labeled warning worth knowing if you're considering higher doses.

Sources

1. Radiology, 2012, methylene blue and fMRI memory study: Low-dose (~0.5 mg/kg) oral methylene blue increased fMRI activity and improved memory task performance in healthy adults
2. The Lancet Neurology, 2018, LMTX Phase 3 Alzheimer's trials: Two Phase 3 trials of methylene blue-related LMTX in over 1,100 Alzheimer's patients found no clear benefit as add-on therapy
3. TauRx, LMTX frontotemporal dementia Phase 3 trial results: A later trial of LMTX in behavioral variant frontotemporal dementia did not meet its primary endpoint
4. Pharmacology review, methylene blue mitochondrial electron transport mechanism: Methylene blue can act as an alternative electron carrier in the mitochondrial respiratory chain in cell and animal models
5. FDA Drug Safety Communication, 2011, methylene blue and serotonergic drug interaction: FDA warns methylene blue can cause serious serotonin syndrome interactions with SSRIs, SNRIs, and other serotonergic medications
6. CDC, G6PD deficiency fact sheet: G6PD deficiency affects an estimated hundreds of millions of people worldwide and is a contraindication for methylene blue